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Abstract
Background: MazF is an endoribonuclease encoded by Escherichia coli that specifically cleaves the ACA sequence of mRNA.
In our previous report, conditional expression of MazF in the HIV-1 LTR rendered CD4+ T lymphocytes resistant to HIV-1
replication. In this study, we examined the in vivo safety and persistence of MazF-transduced cynomolgus macaque CD4+ T
cells infused into autologous monkeys.
Methodology/Principal Findings: The in vivo persistence of the gene-modified CD4+ T cells in the peripheral blood was
monitored for more than half a year using quantitative real-time PCR and flow cytometry, followed by experimental autopsy
in order to examine the safety and distribution pattern of the infused cells in several organs. Although the levels of the
MazF-transduced CD4+ T cells gradually decreased in the peripheral blood, they were clearly detected throughout the
experimental period. Moreover, the infused cells were detected in the distal lymphoid tissues, such as several lymph nodes
and the spleen. Histopathological analyses of tissues revealed that there were no lesions related to the infused gene
modified cells. Antibodies against MazF were not detected. These data suggest the safety and the low immunogenicity of
MazF-transduced CD4+ T cells. Finally, gene modified cells harvested from the monkey more than half a year post-infusion
suppressed the replication of SHIV 89.6P.
Conclusions/Significance: The long-term persistence, safety and continuous HIV replication resistance of the mazF gene-
modified CD4+ T cells in the non-human primate model suggests that autologous transplantation of mazF gene-modified
cells is an attractive strategy for HIV gene therapy.
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Introduction
Highly active anti-retroviral therapy (HAART) is widely used
for human immunodeficiency virus (HIV) therapy and involves the
combination of several drugs with different functions that are
currently being evaluated in clinical trials; some of these drugs are
currently available [1]. HAART treatment reduces plasma viral
load to undetectable levels and recovers CD4+ T cells to clinically
safe levels. Although HAART therapy has revolutionized the
treatment of HIV-1 infection, the need for life-long therapy,
difficulties with medication adherence and long-term medication
toxicities have led to the search for new treatment strategies that
will efficiently reduce the viral load and allow for stable
immunological homeostasis. The number of patients who are
HAART resistant has significantly decreased in the past 2 years
due to newly available drugs, but based on previous experience,
drug resistance is likely to increase again. Thus, additional
approaches for the management of HIV infection, or approaches
performed in combination with HAART therapy, are needed.
Gene therapy for HIV-1 infection has been proposed as an
alternative to antiretroviral drug regimens [2,3]. A number of
different genetic vectors with antiviral payloads have been utilized
to combat HIV-1, including antisense RNA against the HIV-1
envelope gene, transdominant protein RevM10, ribozymes, RNA
decoys, single chain antibodies, and RNA-interference [4,5].
These protocols use T cells or hematopoietic stem cells as a target
for gene modification. Autologous T cell transfer in HIV patients
began in the mid 1990’s, and since that time, no serious adverse
events have been reported to be associated with infusions of
autologous T cells, and infusions are well tolerated. The majority
of these clinical trials used gene transfer by retrovirus or lentiviral
vectors for the delivery of the anti-HIV payloads.
In order to develop a new approach for HIV therapy, we
previously constructed an HIV-1 Tat-dependent expression
retroviral vector in which the Escherichia coli (E. coli) endoribonu-
clease gene mazF was fused downstream of the trans-activation
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induced upon HIV-1 replication [6]. When MazF-transduced cells
were infected with HIV-1 IIIB, the replication of HIV-1 was
efficiently inhibited without affecting CD4+ T cell growth. MazF-
transduced primary CD4+ T cells derived from monkeys also
suppressed simian/human immunodeficiency virus (SHIV) repli-
cation [6]. Thus, autologous transfer of genetically modified CD4+
T cells conditionally expressing the MazF protein will be a
promising strategy for HIV gene therapy. Generally, the shift from
the chronic phase to the AIDS phase is due to the balance between
viral growth and immune suppression, and the remarkable
decrease in CD4+ T cells causes the subsequent deficiency of
the immune system, the hallmarks of AIDS. The benefit of the
MazF-based gene therapy strategy is that gene-modified CD4+ T
cells may be protected from HIV-1-associated cell death and are
therefore likely to help the immune system maintain a stable
condition.
In this preclinical study, we examined the in vivo safety and
persistence of MazF-transduced autologous CD4+ T cells (named
MazF-Tmac cells) using a non-human primate model. Cynomol-
gus macaque primary CD4+ T cells were retrovirally transduced
with the MazF vector, infused into the autologous monkeys, and
the persistence and safety of the MazF-Tmac cells was monitored
more than half a year. We found that infused MazF-Tmac cells
were detected in the peripheral blood throughout the experimental
period. Additionally, experimental autopsy revealed the distribu-
tion of the infused lymphocyte in total body.
Results
Manufacturing of MazF-transduced CD4+ T cells using ex
vivo-expanded cynomolgus macaque CD4+ T cells
In order to infuse more than 1610
9 MazF-transduced
autologous cells, isolated primary CD4+ T lymphocytes were ex
vivo stimulated, transduced with the MT-MFR-PL2 retroviral
vector (Figure 1A), and expanded as described in the Materials
and Methods. The resultant MazF-Tmac cells were transplanted
into autologous monkeys via intravenous infusion (Figure 1B). We
initially used concanavalin A (Con A) for the stimulation of CD4+
T cells (CD4T-1), but Con A only induced a 12-fold cell expansion
after 7 days. In order to improve the ex vivo expansion, we used
anti-CD3/anti-CD28 monoclonal antibody-conjugated beads
(anti-CD3/CD28 beads), which are known to yield a more
efficient cellular expansion [7,8]. As we expected, the fold
expansion of CD4+ T cells (CD4T-2 and CD4T-3) stimulated
with anti-CD3/CD28 beads was much higher than with Con A
stimulation (Table 1). In order to improve the engraftment
efficiency of CD4+ T cells, busulfan was orally administered to the
macaques prior to the transplantation, and the gene-modified
MazF-Tmac cells were infused into each monkey intravenously at
1.6–2.7610
9 cells.
Transduction efficiency and cell surface markers of MazF-
Tmac cells
The efficiency of MazF transduction and phenotype of cell
surface markers of the MazF-Tmac cells were analyzed using flow
cytometry. The MazF vector transduction efficiency of CD4T-2
and CD4T-3 cells was 61.8% and 60.0%, respectively, while only
34.5% for CD4T-1 (Table 1). As shown in Table 2, 99% of the
expanded MazF-Tmac cells were CD3 and CD4 double-positive,
and in these cells, more than 90% expressed CD95/CD28, which
are known central memory phenotype markers [9]. Central
memory cells generally have a longer life span compared to
effecter memory cells [10]; thus, a higher percentage of central
memory cells in MazF-Tmac cells is likely to result in longer
persistence after transplantation. Furthermore, to assess the
activation status of MazF-Tmac cells, we measured the expression
of CD25, which is also known as IL-2 receptor alpha and is an
activated T cell marker. CD25 expression of MazF-Tmac cells
from CD4T-2 and CD4T-3 was low. In contrast, almost 100% of
the CD4+ T cells were found to express CD25 with a higher
expression level 2–4 days after stimulation (data not shown). Thus,
these data indicate that a large number of MazF-Tmac cells
entered into resting or non-activated states during the ex vivo
culture. CXCR4, a co-receptor for X4 tropic HIV entry, was
found to be expressed in expanded CD4T-2 and CD4T-3 MazF-
Tmac cells. Furthermore, we observed that there was no
significant difference in the measured cell surface markers between
Con A- and anti-CD3/CD28 bead-stimulated MazF-Tmac cells
(Table 2).
Longitudinal analysis of infused MazF-Tmac cells
To examine the in vivo safety and persistence of infused MazF-
Tmac cells, peripheral blood from each monkey was collected to
monitor the hematological effects and the proviral copy number of
the transduced retroviral vector in the genome over six months.
There was no significant change in the body weight of the
monkeys throughout the experiment (Figure 2A). During the
period of 2–4 weeks post-transplantation, severe reduction in the
white blood cell (WBC) count, hemoglobin (Hb) concentration,
and platelet (PLT) levels were observed in the monkeys CD4T-1
and CD4T-2, while only slight reduction was observed in CD4T-
3. These negative effects are considered to be due to the effect of
the busulfan treatment, which is known to cause partial bone
marrow depletion and functional defects in blood-forming tissues.
No other adverse events were observed throughout the experi-
ments. The transient reduction of lymphocytes gradually recov-
ered, and the cell number became stable two months after the
transplantation (Figure 2A).
The percentage of persistent MazF-Tmac cells in CD4+ T cells
was determined using real-time PCR and flow cytometric analyses.
The percentage of MazF-Tmac cells gradually decreased in
CD4T-1- and CD4T-2-transplanted monkeys, while in the
CD4T-3-transplanted monkey, a drastic reduction of the infused
MazF-Tmac cells was observed 3–4 weeks post-transplantation but
was not observed at later time points (Figure 2B). Although the
levels of MazF-Tmac cells gradually decreased over time, the
infused MazF-Tmac cells were detected even after six months
post-transplantation. It is reasonable to assume that a population
of infused MazF-Tmac cells can persist for a long-term period,
likely forming a resting condition.
Detection of anti-MazF antibodies in monkey blood
Although the levels of MazF-transduced CD4+ T cells gradually
decreased in the peripheral blood, some were detected throughout
the half-year experimental period, suggesting that MazF-Tmac
cells showed little or no immunogenicity towards cynomolgus
macaques. Because gene therapy for HIV is aimed at reconstitut-
ing an HIV-resistant immune system, genetically modified cells
must not only inhibit virus replication, but also maintain their
expected trafficking behavior and persist in vivo. Although the
evidence of longitudinal persistence of MazF-Tmac cells supports
the low immunogenicity of MazF-Tmac cells, it is important to
assess the production of antibodies against MazF. As shown in
Figure 3 and Figure S1, we detected no production of anti-MazF
antibodies in the CD4T-2 monkey blood after transplantation of
the MazF-Tmac cells.
RNase Based Gene Therapy of HIV
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It is a great advantage to use primate models for investigating
the safety of gene-modified cells, as they can be used for surgical
pathological analysis. Therefore, we performed experimental
autopsies six months after transplantation. To examine the safety
of MazF-Tmac cells, specimens from several organs were fixed in
buffered formaldehyde and embedded in plastic. Serial sections
were made using a diamond saw. Slides were then stained with
hematoxylin-eosin. Histopathological findings of the specimens
were contracted with Bozo Research Center (Tokyo, Japan), and
no severe adverse events relating to MazF-Tmac cell infusion was
observed (Table 3 and Figure S2).
Examination of the anti-viral efficacy of MazF-Tmac cells
harvested from monkey
In order to examine whether the Tat-dependent expression of
MazF and anti-viral efficacy was maintained in the MazF-Tmac
cells after infusion, CD4+ T lymphoid cells from a CD4T-1-
transplanted monkey (214 days post-infusion of MazF-Tmac cells)
were selected and expanded ex vivo (Figure 4A). After 7 days of
expansion, the genetically modified cells expressing a truncated
form of the human low affinity nerve growth factor (DLNGFR+)
were concentrated with an anti-CD271 monoclonal antibody
(Figure 4B). CD271-positive cells and CD271-negative cells were
expanded for an additional 4 days. Both groups of expanded cells
were infected with SHIV 89.6P [11] at the multiplicity of infection
(MOI) of 0.01. Culture supernatants and cell pellets were analyzed
at 6 days post-infection. As shown in Figure 4C, the replication of
SHIV 89.6P was significantly suppressed in CD271-positive cells
Table 1. Demographic data and summary of expansion fold
and transduction efficiency.
CD4T-1 CD4T-2 CD4T-3
Body Weight (kg) 5.25 5.18 3.7





CD4+ T cells (610
7 cells)
13.0 1.0 4.6





Expansion Fold 12.3 170 58.7
Gene transfer efficiency (%) 34.5 61.8 60.0
doi:10.1371/journal.pone.0023585.t001
Figure 1. Diagram of autologous CD4+ T cell transplantation using a non-human primate model. (A) Design of gene transfer vector. The
MazF gene derived from E. coli was inserted directly into the downstream of HIV-LTR sequence. The HIV-LTR-MazF-polyA cassette was introduced in
the opposite direction of the MoMLV-LTR. A truncated form of the human DLNGFR was also introduced into the retrovirus vector as a surface marker.
The DLNGFR gene is under the control of the human PGK promoter. (B) Flow diagram of gene-transduced CD4+ T cell manufacture. (1) Peripheral
blood was collected by apheresis, (2) CD4+ T cells were selected by positive selection and stimulated ex vivo with Con A or anti-CD3/CD28
monoclonal antibody-conjugated beads. (3) The MT-MFR-PL2 vector was transduced twice on days 3 and 4. (4) The transduced cells were expanded
for an additional 3–5 days until the total cell number reached more than 10
9. (5) On day 7–9, the expanded cells were collected, washed, and infused
to the autologous macaques through venous blood.
doi:10.1371/journal.pone.0023585.g001
Table 2. Cell surface markers of expanded MazF-Tmac cells.
CD4T-1 CD4T-2 CD4T-3
CD3(+)/CD4(+) (%) 98.2 98.7 99.9
CD95(2)/CD28(+)( N a ı ¨ve) (%) 0.7 1.2 0.4
CD95(+)/CD28(+) (CM) (%) 93.0 94.7 91.2
CD95(+)/CD28(2) (EM) (%) 6.2 3.9 8.3
CXCR4 (%) N/A 92.0 79.4
CD25 (%) N/A 30.4 24.5
CM: Central Memory, EM: Effector Memory.
doi:10.1371/journal.pone.0023585.t002
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analysis managed to detect the expression of MazF, MazF was
below the detection limit (data not shown). However, the
expression of MazF was clearly induced when the same CD271-
positive cells were transduced with the Tat expression retroviral
vector M-LTR-Tat-ZG [6] (Figure 4D). These data suggest that
the conditional expression system in MazF-Tmac cells is still active
at 6 months post-transplantation.
Distribution of MazF-Tmac cells
To examine the distribution and persistence of the infused
MazF-Tmac cells in a monkey, lymphocytes isolated from several
organs were analyzed using flow cytometry and real-time PCR. As
shown in Figure 5A and 5B, DLNGFR+ cells were detected in
CD4+ T cells isolated from several lymph nodes (LNs), spleen, and
peripheral blood. A similar tendency was obtained using real-time
PCR (Figure 5C). In contrast, MazF-Tmac cells were not detected
in the bone marrow, liver, thymus, and small intestine (data not
shown). These data strongly suggest that infused MazF-Tmac cells
mainly circulate in the secondary lymphoid organs.
In vivo distribution of MazF-Tmac cells treated with or
without retinoic acid
Based on the findings that MazF-Tmac cells were well
distributed among secondary lymphoid organs but not in small
intestine, we performed additional experiment using one cyno-
molgus monkey (CD4T-4). In order to investigate the editing effect
of the homing receptor to efficiently recruit the gene-modified cells
to intestinal tissues in a non-human primate model, the
distribution of retinoic acid-treated MazF-Tmac cells was
Figure 2. Hematological analysis and engraftment of the MazF-transduced CD4+ T cells. (A) The body weight and several hematological
features were measured at the indicated time points, and the number of WBC, Hb, and PLT were represented. Each macaque was monitored
throughout the study period. (B) The in vivo persistence of retroviral-transduced CD4+ T cells in the peripheral blood. PBMCs were collected at the
indicated time points. The percentage of CD4+ T cells was analyzed using flow cytometry, and the proviral MazF vector copy was analyzed using real-
time PCR. By compounding these two data, the copy number of the mazF gene in CD4+ T cells was calculated.
doi:10.1371/journal.pone.0023585.g002
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is described in Figure 6A. Non-treated and retinoic acid-treated
MazF-Tmac cells were designated as MazF-Tmac-N and MazF-
Tmac-R, respectively. Expressions of integrin-a4 and integrin-b7
were remarkably increased in the presence of retinoic acid
(Figure 6B). Thereafter, MazF-Tmac-N and MazF-Tmac-R were
labeled with carboxyfluorescein diacetate succinimidyl ester
(CFSE) and PKH26, respectively. The CFSE-labeled cells were
mixed with an equal number of PKH26-labeled cells (Figure 6C),
and 6.8610
8 of the mixed cells were infused into a CD4T-4
monkey. Note that the transduction efficiency of the MazF vector
was 65% (data not shown). Three days after the transplantation,
experimental autopsy was performed to obtain samples of several
organs as described in the Materials and Methods. Both the
CFSE- and the PKH26-labeled CD4+ T cells were detected in the
peripheral blood and several LNs by FACS analysis (Figure 6D).
The percentage of the infused cells in the LNs was low compared
to the peripheral blood, indicating that a large number of the
infused cells did not migrate to the secondary lymphoid tissues and
circulated in the peripheral blood at this time point. In the case of
the inguinal and axillary LNs, the percentage of MazF-Tmac-R
cells was low compared to MazF-Tmac-N cells. In contrast, a
higher percentage of MazF-Tmac-R cells was observed in the
mesenteric LN compared to MazF-Tmac-N cells. MazF-Tmac-N
cells were evenly distributed in the three LNs analyzed, while the
MazF-Tmac-R cells seemed to be preferentially distributed in the
mesenteric LNs. Moreover, a large number of MazF-Tmac-R cells
were distributed in the small intestine, while MazF-Tmac-N cells
were not. To further evaluate the homing effect of the MazF-
Tmac cells, the distribution of the labeled-MazF-Tmac cells in
cryopreserved organs was analyzed using fluorescence microscopy
(Figure 6E). A number of the PKH26-labeled MazF-Tmac-R cells
were observed in the mesenteric LNs and in Peyer’s patches.
Taken together, retinoic acid-treated MazF-Tmac cells seem to be
selectively recruited to mesenteric LNs and then transported to
Peyer’s patches. The distribution of MazF-Tmac-R cells in the
intestinal villi remains to be determined.
Discussion
MazF is a toxin encoded by the E. coli genome and plays a role
in growth regulation under stress conditions in E. coli [12]. MazF
can act as an endoribonuclease (RNase) that specifically cleaves
cellular mRNAs at ACA sequences [13]. Therefore, MazF
induction in E. coli virtually eliminates almost all cellular mRNAs
to completely inhibit protein synthesis. However, MazF-induced
cells retain full capacity for protein synthesis, as MazF-induced
cells are able to produce a protein at a high level if the prerequisite
mRNA is engineered to be devoid of all ACA sequences without
altering its amino acid sequence [14]. This indicates that RNA
components involved in protein synthesis are protected from
Figure 3. No detection of anti-MazF antibodies in monkey blood after transplantation of MazF-Tmac cells. Plasma samples were
isolated from the monkey CD4T-2 at day 0, 33, 75, and 103 after transplantation and were used to detect anti-MazF antibodies on a MazF protein-
immobilized microplate. The plasma samples were diluted to 500,000-fold, 50,000-fold, and 10,000-fold and added to each well. After the incubation,
antibodies which reacted with immobilized MazF were tried to detect as described in Materials and Methods. No MazF-specific antibodies were
detected.
doi:10.1371/journal.pone.0023585.g003





Bone marrow ++** 22
Thymus N/A +* 2
Small intestine 222
Liver 222
Kidney 2 6 2
Pancreas 222
Stomach 226
Lung 2 6 2
Heart 226
2: No remarkable changes; 6: Minimal; +:M i l d ;++: Moderate.
N/A: No equivalent sample available.
*Due to the Aging,
**Side effect due to the busulfan administration.
doi:10.1371/journal.pone.0023585.t003
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RNAs (tRNAs) are protected from MazF cleavage in E. coli [15].
RNase-based anti-HIV gene therapy is an attractive strategy to
suppress HIV-1 RNA replication. In the case of MazF, there are
more than 240 ACA sequences in HIV-1 RNA, suggesting that
HIV has almost no chance to gain MazF-related escape mutations.
This approach seems to have a substantial advantage over the
other known antiviral strategies, including antiviral drug therapy,
and RNA-based gene therapies, such as antisense RNA, ribozyme,
and siRNA.
MazF overexpressed in mammalian cells preferentially cleaves
messenger RNAs (mRNAs), but not ribosomal RNAs [16]. As
HIV-1 RNA has more than 240 ACA sequences, we assumed that
the viral RNA is highly susceptible to MazF, leading to inhibition
of viral replication under a conditional expression system. Indeed,
conditional expression of MazF with Tat suppresses replication of
both HIV-1 IIIB and SHIV 89.6P without affecting cellular
mRNAs, suggesting that this Tat-dependent expression system of
MazF is an attractive payload for HIV gene therapy [6]. It is an
intriguing phenomenon that viral RNAs are efficiently and
preferentially cleaved without affecting cellular mRNAs, and we
are now addressing this question. Meanwhile, MazF is a bacterial
protein, and its expression is induced by Tat protein; thus, it is
important to assess the safety and immunogenicity of mazF gene-
modified cells in vivo. In order to determine the safety of our MazF-
retrovirus system in vivo, we infused MazF-transduced CD4+ T
cells into cynomolgus macaques. In human gene therapy trials,
engraftment of 1–2% of genetically modified cells in the peripheral
Figure 4. Examination of the anti-viral efficacy of MazF-Tmac cells harvested from the monkey. (A) Flow diagram of the experiment.
CD4+ T lymphoid cells from CD4T-1 (214 days post-infusion of the MazF-Tmac cells) were stimulated and expanded ex vivo. The genetically modified
cells expressing DLNGFR+ were concentrated with an anti-CD271 monoclonal antibody and expanded for 4 days. The expanded CD271-enriched cells
and CD271-negative cells were infected with SHIV 89.6P. SHIV RNA levels in the culture supernatant were determined using quantitative real-time
PCR. Expression of MazF was detected from the cell lysates by western blot analysis. Moreover, CD271-positive cells were transduced with the Tat
expression vector. (B) CD271-positive and -negative cells were enriched using an anti-CD271 antibody, and dot plots of the flow cytometry analysis
are presented. (C) The suppression of SHIV RNA in the culture supernatant at 6 days after infection was detected by real-time PCR analysis. (D) MazF-
Tmac cells transduced with the Tat expression vector were harvested at 20 hours post-transduction and used for western blot analysis. Conditional
expression of MazF in a Tat-dependent manner was observed.
doi:10.1371/journal.pone.0023585.g004
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billion cells [17], and higher cell doses results in higher levels of
engraftment [18,19]. Infusions of lower than 5610
9 cells do not
reliably result in measurable engraftment levels [19]. Therefore,
we decided to infuse more than one billion cells into cynomolgus
macaques, reflecting one-tenth of the scale of the human model.
Indeed, the mazF gene-modified cells were detected over a six
month period at a high level, and no histopathological disorders
and no MazF-specific antibody production was observed during
the experiment, demonstrating that MazF-Tmac cells showed little
or no immunogenicity to monkeys. Moreover, MazF-Tmac cells
harvested from the CD4T-1-transplanted monkey 6 months post-
infusion showed resistance to the replication of SHIV 89.6P,
indicating that the long-term persistent MazF-Tmac cells are
functional. The expression of MazF in the SHIV-infected MazF-
Tmac cells was below the limit of detection due to a low MOI such
as 0.01, while in the MazF-Tmac cells transduced with the Tat
expression retroviral vector M-LTR-Tat-ZG at 45% efficiency,
expression of MazF was clearly induced, indicating that Tat
dependent MazF expression system was maintained in the cells
even 6 months after the autologous transplantation.
Because gene therapy for HIV is aimed at reconstituting an
HIV-resistant immune system, genetically modified cells must
inhibit virus replication and maintain persistence in vivo. Although
ex vivo gene therapy targeting CD4+ T cells or CD34+
hematopoietic stem cells has been shown to promote long term
persistence of infused cells in peripheral blood in human, it is
difficult to obtain information about the distribution pattern of
these cells in the whole human body. In order to obtain such
information, the monkeys were sacrificed and lymphocytes were
isolated from several organs after 6 months of monitoring.
Importantly, the infused MazF-Tmac cells were detected in
secondary lymphoid tissue, such as several LNs and spleen, and in
peripheral blood, although individual differences between CD4T-
1, -2, and -3-transplanted monkeys were observed. No histopath-
ological disorders were observed in the organs containing MazF-
Tmac cells, indicating that there were no lesions relating to MazF-
Tmac cells. The distribution of MazF-Tmac cells in the lymphoid
tissues of CD4T-3-transplanted monkey was lower compared to
the CD4T-1 and -2-transplanted monkeys. One reason for this
phenomenon is likely the lower dosage of busulfan used to treat the
CD4T-3-transplated monkey. Busulfan is an alkylating agent with
potent effects on hematopoietic stem cells that is commonly used
for stem cell transplantation. In rhesus macaques, a low-dose of
busulfan has an impact on bone marrow stem/progenitor cells
with transient and mild suppression of peripheral blood counts
Figure 5. Analysis of the distribution of MazF-Tmac cells in several organs. (A) CD4+ T cells were isolated from lymphocytes separated from
several organs, incubated 3–4 days, and stained with anti-CD4 and anti-CD271 antibodies. CD4T-2 is represented by a dot plot. (B) The percentage of
CD271+ cells from three macaques is summarized. (C) The Copy number of the MazF gene in CD4+ T cells from each organ was calculated from real-
time PCR and flow cytometric data.
doi:10.1371/journal.pone.0023585.g005
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Tmac) cells might be due to the milder busulfan treatment.
In contrast to the LNs and spleen, a limited number of cells
were detected in non-lymphoid tissues such as small intestine and
liver. Considering HIV-1 infection, the gastrointestinal (GI) tract,
which contains the vast majority of lymphoid tissues in the total
body to protect mucosal membranes from foreign antigens, is the
dominant site of HIV replication rather than LNs, which were
originally thought to be the main infection sites [21]. In GI tract,
CD4+ T cells are dramatically decreased during the acute phase of
HIV infection [21,22,23]. In rhesus macaques, a similar depletion
was also reported during the acute phase of simian immunode-
ficiency virus (SIV) infection, with CD4+ memory T cells
specifically targeted [24,25]. Notably, the rate of mucosal CD4+
Figure 6. Comparison of the homing effect of MazF-Tmac cells treated with or without retinoic acid. (A) CD4+ T cells from the CD4T-4
monkey were stimulated with anti-CD3/CD28 beads, and MT-MFR-PL2 vector was transduced twice on days 3 and 4. After transduction, total
lymphocytes were divided into two culture conditions in which retinoic acid was added to the one. After an additional 5 days of incubation, control
and retinoic acid-treated cells were stained with CFSE and PKH26, respectively, mixed at nearly the same numbers, and infused into the autologous
CD4T-4. Three days after the transplantation, experimental autopsy was performed. (B) A mixture of the two groups of MazF-Tmac cells stained with
CFSE and PKH26 was analyzed using flow cytometry; the ratio of the two groups was almost same. (C) Up-regulation of the homing receptor was
confirmed in the MazF-Tmac-R cells. The MazF-Tmac-N and MazF-Tmac-R cells are indicated by the blue line and red line, respectively. (D)
Lymphocytes were collected from three lymph nodes (LNs) and small intestines, and a percentage of fluorescently-labeled cells were analyzed by
flow cytometry. (E) Fluorescence microscope analysis of distal organ specimens.
doi:10.1371/journal.pone.0023585.g006
RNase Based Gene Therapy of HIV
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with the disease progression in the rhesus macaque [26]. Indeed,
recent studies provide evidence that the depletion of mucosal
CD4+ T cells leads to damage of the gut mucosal layer resulting in
translocation of microbial products, such as lipopolysaccharide
(LPS), ultimately causing chronic and systemic immune activation,
which is one of the hallmarks of HIV/SIV infection and one of the
predictors of disease progression [27,28]. Although HAART
therapy is effective in controlling viral replication and recovering
CD4+ T cells in the peripheral blood, restoration of CD4+ T cells
is delayed in the GI tract [21,29]. Thus, the repair of depleted
CD4+ T cells using gene therapy might attenuate the breakdown
of the mucosal layer and prevent mucosal immune system
deficiency. To change the tissue distribution of infused CD4+ T
cells, the enhancement of homing receptor expression in T
lymphocyte is necessary. Integrin a4b7 is known to facilitate the
migration of lymphocytes from gut-inductive sites where immune
responses are first induced (Peyer’s patches and mesenteric LNs) to
the lamina propria [30,31]. Expression of the homing receptor is
induced by the addition of retinoic acid [32], which is produced
mainly from retinol (vitamin A) by dendritic cells in the mesenteric
LNs. As shown in Figure 6D and 6E, although these are
preliminary data with only one monkey, editing of the homing
receptors integrin-a4 and integrin-b7 by retinoic acid enhanced
the recruitment of MazF-Tmac cells to the mesenteric LNs, small
intestine, and Peyer’s patches. These results may indicate that
MazF-Tmac cells treated with retinoic acid selectively accumulate
in the mesenteric LNs and then migrate into Peyer’s patches. It has
been reported that the HIV-1 envelope protein gp120 binds to and
signals through the activated form of integrin a4b7 [33]; however,
we expect that retinoic acid-treated MazF-T cells will persist in
distal organs without the additional spread of HIV replication
because of the HIV-1 resistance observed in the MazF-Tmac cells.
Therefore, we speculate that the combination of several culture
methods to edit the homing receptor will enhance the recruitment
of MazF-Tmac cells to distal lymphoid organs, resulting in a more
efficient therapeutic.
In summary, we showed long-term persistence, safety and
continuous HIV replication resistance in the mazF gene-modified
CD4+ T cells in a non-human primate model in vivo, suggesting
that autologous transplantation of mazF gene-modified cells is an
attractive strategy for HIV gene therapy.
Materials and Methods
Vector design and viral production
The GALV-enveloped gamma retroviral vector MT-MFR-LP2
was generated as previously described [6]. MT-MFR-PL2
expresses a truncated form of the human low affinity nerve
growth factor gene (DLNGFR) [34] under the control of a
functional PGK promoter and the MazF gene under control of the
HIV-LTR promoter (Figure 1A). The DLNGFR is a surface
marker that allows identification of transduced cells.
Animals
Four cynomolgus macaques (Macaca fascicularis, 6–7 years old),
CD4T-1, CD4T-2, CD4T-3, and CD4T-4, were used in this
experiment and were maintained at the Tsukuba Primate
Research Center for Medical Science at the National Institute of
Biomedical Innovation (NIBIO, Ibaraki, Japan). The study was
conducted according to the Rules for Animal Care and the
Guiding Principles for Animal Experiments Using Nonhuman
Primates formulated by the Primate Society of Japan [35] and in
accordance with the recommendations of the Weatherall report,
‘‘The use of non-human primates in research’’. The protocols for
the experimental procedures were approved by the Animal
Welfare and Animal Care Committee of the National Institute
of Biomedical Innovation (DS18-100). All surgical and invasive
clinical procedures were conducted by trained personnel under the
supervision of a veterinarian in a surgical facility using aseptic
techniques and comprehensive physiologic monitoring. Ketamine
hydrochloride (Ketalar, 10 mg/kg; Daiichi-Sankyo, Tokyo, Japan)
was used to induce anesthesia for all clinical procedures associated
with the study protocol such as blood sampling, gene-modified cell
administration, clinical examinations and treatment.
Ex vivo expansion of CD4+ T cells, and transduction of
the MazF vector
Peripheral blood from cynomolgus macaques was collected by
apheresis as previously described [36]. For the dissolution of red
blood lymphocytes, collected blood was treated with ACK lysing
buffer (Lonza, Walkersville, MD) and was washed twice with
phosphate buffered saline (PBS). Then, CD4+ T cells were isolated
using anti-CD4 conjugated magnetic beads (Dynal CD4 Positive
Isolation Kit, Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Isolated CD4+ T cells were cultured
at 5610
5 cells/ml in GT-T503 (Takara Bio, Otsu, Japan)
supplemented with 10% FBS (Invitrogen), 200 IU recombinant
human interleukin-2 (IL-2; Chiron, Emeryville, CA), 2 mM L-
glutamine (Lonza), 2.5 mg/ml Fungizone (Bristol Myers-Squibb,
Woerden, The Netherlands) and activated for three days with
either 5 mg/ml concanavalin A (Con A, Sigma Chemical, St.
Louis, MO) for CD4T-1 or a combination of anti-CD3 clone FN-
18 (Biosource, Camarillo, CA, USA) and anti-CD28 clone L293
(BD Biosciences, Franklin Lakes, NJ) monoclonal antibodies
conjugated to M-450 epoxy magnetic beads (Invitrogen) at cell-
to-bead ratio of 1:1 (CD4T-2 and CD4T-3). On day 3, the
activated CD4+ T cells were transduced with the MazF retroviral
vector MT-MFR-PL2 in the presence of RetroNectinH (Takara
Bio) according to manufacturer’s instructions. Transduction was
repeated on day 4. CD4+ T cells were further expanded to day 7
to 9 until the total cell number reach more than 10
9. The closed
system MazF-Tmac cell manufacturing was performed using gas
permeable culture bags; Cultilife 215 (Takara Bio) and Cultilife
Eva (Takara Bio) were used for CD4+ T cells expansion and
Cultilife spin (Takara Bio) was used for transduction of the MazF
retroviral vector.
Transplantation of expanded CD4+ T cells
Prior to the transplantation, each macaque was treated with
busulfan (Ohara Pharmaceutical, Shiga, Japan). Busulfan has been
used extensively as a preparatory regimen for allogenic hemato-
poietic stem cell transplantation based on its toxicity to
hematopoietic stem cells. Furthermore, it has been reported that
in non-human primates, hematopoiesis was significantly decreased
after a single, clinically well-tolerated dose of busulfan, with slow,
but almost complete, recovery over the next several months [20].
The effects of busulfan on lymphocyte engraftment, however, are
not well documented. Although cyclophosphamide is widely used
in immune gene therapy trials in humans for lymphocyte
transplantation, there is no information available for cyclophos-
phamides effect on T-cell transplantation in the cynomolgus
macaque. It should be noted that we have chosen busulfan for our
CD4+ T cell transplantation because busulfan is shown to cause a
reduction in the peripheral blood count in human trial [37], we
have had success in using busulfan for cynomolgus macaque bone
marrow transplantation and according to internal information,
busulfan causes a reduction of the peripheral blood count in
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macaques twice at 10 mg/kg each (CD4T-1 and CD4T-2) or
6 mg/kg each (CD4T-3) [38]. The expanded cells were harvested,
washed three times with PBS, and re-suspended in PBS containing
10% autologous plasma. The collected cells were infused
intravenously to monkeys at the speed of 1 ml per minute.
Flow cytometry analysis
The cell surface markers of the expanded cells and peripheral
blood mononuclear cells (PBMC) were analyzed using FACSCa-
libur (BD Bioscience) and FACSCanto (BD Bioscience), and data
analysis was performed using CellQuest software (BD Bioscience),
FACSDiva software (BD Bioscience) or FlowJo software (Tree
Star, Inc., Ashland, OR). The following antibodies were used for
staining: anti-CD3 (SP34-2, PerCP), anti-CD4 (L200, FITC), anti-
CD25 (2A3, FITC), anti-CD28 (CD28.2, PE), anti-CD95 (DX2,
FITC), anti-CXCR4 (12G5, PE) and anti-integrin-b7 (FIB504,
PE), which were obtained from BD Bioscience. The anti-CD49d
(HP2/1, FITC) antibody was obtained from Beckman Coulter
(Fullerton, CA), and the anti-CD271 (LNGFR, PE and APC)
antibodies were obtained from Miltenyi Biotec GmbH (Bergisch
Gladbach, Germany).
Measurement of hematological data
Two ml of blood was prepared every week. Blood samples were
used to measure the white blood cell (WBC) count, red blood cell
(RBC) count, hemoglobin (Hb) concentration, hematocrit values,
mean corpuscular volume, mean cell hemoglobin concentration
and platelet (PLT) count using a Sysmex K-4500 instrument (Toa-
iyouddenshi, Kobe, Japan). The concentrations of the biochemical
markers in blood samples were also monitored including total
proteins, albumin, blood urea nitrogen, glucose, glutamic
oxaloacetic transaminase, glutamic pyruvic transaminase, alkaline
phosphatase, creatine phosphokinase, lactate dehydrogenase,
creatine, sodium, potassium, chlorine and C-reactive protein
using an AU400 instrument (Olympus Medical Systems, Tokyo,
Japan).
Quantification of gene-modified CD4+ T cells
The existence and persistence of genetically modified CD4+ T
cells were monitored by measuring the proviral genome of the
transgene using quantitative real-time PCR. DNA samples were
extracted from 2610
6 PBMCs using a Gentra Puregene Blood Kit
(QIAGEN, Hilden, Germany). The proviral copy number of the
transgene was calculated from 400 ng of genomic DNA with
quantitative PCR using a Cycleave RT-PCR Core Kit (Takara
Bio) and Provirus Copy Number Detection Primer Set (Takara
Bio) according to the manufacturer’s instructions. The reaction
was performed with the Thermal Cycler Dice Real Time System
(Takara Bio), and the data was analyzed using Multiplate RQ
software (Takara Bio). For each run, a standard curve was
generated from the pMT-MFR-PL2 plasmid, whose copy
numbers were already known. Based on the standard curve, the
amount of infused cells was quantified.
Detection of anti-MazF antibodies in macaque blood
after transplantation of MazF-Tmac cells
To examine whether anti-MazF antibodies can be generated
after the transplantation of MazF-Tmac cells, the plasma isolated
from the macaques was analyzed. In order to detect anti-MazF
antibodies, purified MazF protein or anti-monkey IgG (Nordic
Immunological Laboratories, Tilburg, The Netherlands) was pre-
coated onto the wells of a 96-well microplate and subsequently
blocked with PBS-1% BSA. The plasma samples were isolated
from the CD4T-2 at day 0, 33, 75, and 103 after transplantation
and were diluted to 500,000-fold, 50,000-fold, and 10,000-fold.
Cynomolgus macaque IgG purified from normal macaque plasma
with Melon Gel IgG purification Kit (Thermo Fisher Scientific,
Rockford, IL, USA) was used as a control for this reaction. The
two-fold serial dilutions of the IgG (1 ng/ml to 64 ng/ml) and the
diluted plasma samples, as described above, were separately added
to each well. After an overnight incubation at 4uC, the wells were
washed with PBS-1% BSA. The POD-conjugated anti-monkey
IgG (Nordic Immunological Laboratories) was then added to the
wells. After 4 hours of incubation at room temperature, the wells
were washed three times with PBS-1% BSA followed by the
addition of the substrate solution (o-Phenylenediamine, Sigma).
The optical density of each well was read at 490/650 nm using a
680XR microplate reader (Bio-Rad Laboratories, Hercules, CA)
after stopping the reaction with H2SO4 stop solution (Figure S1).
Examination of the anti-viral efficacy of MazF-Tmac cells
harvested from a monkey
To examine the function of the mazF gene in cells harvested
from a MazF-Tmac-transplanted monkey, the frozen lymphoid
cells from CD4T-1 at autopsy (214 days post-infusion of MazF-
Tmac cells) were recovered, CD4+ T cells were selected using a
CD4+ T Cell Isolation Kit (Miltenyi Biotec), stimulated with anti-
CD3/CD28 beads at a cell-to-bead ration of 1:1, and expanded in
GT-T503 medium supplemented with 10% FBS, 200 IU
recombinant human interleukin-2, 2 mM L-glutamine, 2.5 mg/
ml Fungizone, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin. After 7 days of expansion, the genetically modified cells
expressing DLNGFR+ were concentrated with an anti-CD271
monoclonal antibody (CD271 MicroBeads, Miltenyi Biotec) and
expanded for 4 days. The cells from the CD271-negative fraction
were also harvested and expanded as control non-gene modified
CD4+ T cells. The expanded CD271-enriched cells and CD271-
negative cells were infected with SHIV 89.6P at the MOI of 0.01
and cultured for 6 more days. Culture supernatants and cell pellets
were harvested at 6 days post-infection. RNA in the culture
supernatant was recovered with the QIAamp Viral RNA Mini Kit
(QIAGEN) and SHIV RNA levels in the culture supernatant were
determined by quantitative real-time PCR with a set of specific
primers specific for the SHIV gag region [39]. In order to detect
the Tat-dependent expression of MazF in the CD271-enriched
MazF-Tmac cells harvested from the monkey, the cells were
transduced with the Tat expression retroviral vector M-LTR-Tat-
ZG [6] in the presence of RetroNectinH as per the manufacturer’s
instruction. Twenty hours after Tat transduction, the cells were
harvested, counted by trypan blue exclusion assay, washed twice
with PBS, and 5610
5 cells were suspended in 50 mlo f1 6 SDS
sample buffer. The cell samples were incubated at 95uC for
10 min, and 5 ml of each cell sample was used for western blot
analysis. For gel electrophoresis of proteins, the sample solutions
described above were loaded into the wells of a 4–20% Tris-
Glycine gel (Atto, Tokyo, Japan). After completion of electropho-
resis, the gel was transferred to a polyvinylidene fluoride (PVDF)
membrane (Millipore, Billerica, MA) with papers containing
transfer buffer using the semi-dry method at 60 mA (constant
voltage) for 60 min. The membrane was cut in half horizontally
around the 20 kDa protein band of the pre-stained protein marker
(Bio-Rad Laboratories). The upper part of the membrane was
used to detect the a-tubulin (50 kDa) as an internal standard, while
the lower part of the membrane was used to detect MazF
(12 kDa). After blocking, the membranes were then incubated
overnight at 4uC in the blocking buffer (5% skim milk in PBS)
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nology) and 1 mg/ml anti-MazF polyclonal antibody (rabbit, in-
house preparation), respectively. Each membrane was washed
three times and subsequently incubated at room temperature for
1 hour in 10 ml of the blocking buffer containing the 10,000-fold
diluted goat anti-IgG rabbit antibody (peroxidase conjugated,
Thermo Fisher Scientific). The membrane was washed five times
by gentle shaking in the washing buffer at room temperature for
5 min. The membrane was soaked at room temperature for 5 min
in substrate solution (SuperSignal West Femto Maximum
Sensitivity Chemiluminescent Substrate, Thermo Scientific).
Protein signals were detected by a CCD camera (LuminoShot
400 Jr, Takara Bio), which captures a digital image of the western
blot.
Collection of lymphocyte from several organs
Several organs were collected following euthanasia of the
monkeys. After thoracotomy, the right atrium was incised, and 2 L
of heparinized PBS was infused into the left ventricle using an 18-
gauge needle. After perfusion, several organs were collected, and
lymphocytes were separated using the following method: samples
of spleen, thymus, liver, bone marrow, and axillary, inguinal and
mesenteric LNs were minced and filtered through a 40 mm nylon
filter (BD Bioscience); lymphocyte of the small intestine were
collected by the Percoll (GE Healthcare, Castle Hill, Australia)
density-gradient centrifugation method as described previously
[39]; and lymphocytes obtained from each organ were used for the
flow cytometric analysis, and extracted DNA was used for
quantification PCR.
In vivo homing analysis
CD4T-4 was used for homing analysis. Isolated CD4+ T cells
were stimulated with anti-CD3/CD28 beads and cultured in GT-
T503 medium supplemented with 10% FBS, 200 IU IL-2, 2 mM
L-glutamine, and 2.5 mg/ml Fungizone. After 4 days of expansion,
activated CD4+ T cells were divided into two culture bags
(ClutiLife Eva), and 10 nM retinoic acid (Sigma) was added to one
of the bags. After an additional 5 days of incubation, expanded
cells with or without retinoic acid were harvested and labeled with
2 mM PKH26 (Sigma) or 5 mM CFSE (Sigma), respectively,
according to the manufacturer’s instructions. Thereafter, the cells
were washed three times with PBS, mixed in PBS containing 10%
autologous plasma and infused into the macaque. Then, CD4T-4
was euthanized at 3 days after transplantation. Lymphocytes from
several organs were collected as previously described, and the
distributions of labeled lymphocytes were detected by flow
cytometric analysis. The specimens from several organs were
fixed in buffered formaldehyde and embedded in plastic. Serial
sections were made using a diamond saw. The slides were then
analyzed under a fluorescence microscope to detect the distribu-
tion of the expanded cells in the distal organ specimens.
Supporting Information
Figure S1 Raw data of 490/650 nm absorbance. The raw
data of the optical density of each well at 490/650 nm was read
using a microplate reader 680XR (Bio-Rad Laboratories,
Hercules, CA) is represented.
(PDF)
Figure S2 Photographs of histopathological analysis.
Individual photographic data of histopathological analysis of
CD4T-1, -2, and -3 in Table 3 is represented.
(PDF)
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